Key result
Chronic low-grade microvascular inflammation, primarily driven by macrophages and lymphocytes, plays a key role in the pathogenesis of heart failure with preserved ejection fraction.
Why the study?
Effective treatment options for HFpEF remain elusive, and suppressing microvascular inflammation driven by a chronic pro-inflammatory state may represent a novel therapeutic strategy.
Design
Review
Authors
Loading...
Supports microvascular inflammation as a therapeutic target in HFpEF; hypothesis-generating pending randomized trials.
Microvascular inflammation and immune cell activation (macrophages, T-cells, B-cells) play a central role in the pathogenesis of HFpEF, highlighting potential novel anti-inflammatory therapeutic targets.
Овчинников et al. (2020) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Anti-inflammatory and immunomodulatory therapies was evaluated. Chronic low-grade microvascular inflammation, primarily driven by macrophages and lymphocytes, plays a key role in the pathogenesis of heart failure with preserved ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: